AtaGenix Laboratories
AtaGenix Laboratories
Release time: 2026-09-29 View volume: 2
Protein aggregation is one of the most persistent challenges in biopharmaceutical development. Aggregates can reduce potency, trigger immunogenicity, and cause manufacturing failures. This guide explains why proteins aggregate, how to detect aggregates at every stage, and the practical strategies for prevention during expression, purification, and formulation.
Aggregation occurs when partially unfolded or misfolded protein molecules associate through exposed hydrophobic surfaces that are normally buried in the native structure. This can happen through multiple pathways: reversible self-association at high concentration, irreversible non-covalent aggregation driven by thermal or mechanical stress, and covalent aggregation via intermolecular disulfide bond formation or free thiol oxidation. For antibodies specifically, the Fab and hinge regions are common aggregation-prone zones, with CH2 domain unfolding often serving as the nucleation event.
The consequences are significant at every stage. During manufacturing, aggregates foul chromatography resins and clog filtration membranes. In the final drug product, aggregates can present repetitive epitope arrays that cross-link B-cell receptors, breaking immune tolerance and triggering anti-drug antibody (ADA) responses. Regulatory agencies require aggregate levels below 2–5% for clinical material, making aggregation control a critical quality attribute throughout development.
| Stage | Common Causes | Mechanism |
|---|---|---|
| Cell culture | Low pH in late fed-batch, high osmolality, oxidative stress | Partial unfolding under stress conditions in the bioreactor |
| Protein A capture | Low-pH elution (pH 3.0–3.5), abrupt pH transitions | Acid-induced conformational changes expose hydrophobic patches |
| Freeze–thaw | Cryoconcentration, ice–liquid interface stress | Local protein and salt concentration spikes at freezing front |
| Formulation / storage | High concentration (>100 mg/mL), agitation, light exposure | Concentration-dependent self-association; photo-oxidation of Trp/Met |
| Bacterial expression | Rapid overexpression of recombinant protein | Inclusion body formation when folding capacity is overwhelmed |
Size-based methods:
• SEC (size-exclusion chromatography): The workhorse method for quantifying soluble aggregates. Separates monomer from dimer, oligomer, and higher-order species. Required in virtually every lot release panel.
• DLS (dynamic light scattering): Non-invasive measurement of hydrodynamic radius distribution. Useful for detecting early-stage aggregation before SEC-visible species form. Low sample requirement (~50 µL).
Sub-visible and visible particle methods:
• MFI (micro-flow imaging): Counts and images particles in the 1–100 µm range, capturing the “gap” between SEC-detectable soluble aggregates and visible particles.
• Light obscuration (HIAC): Regulatory standard for ≥10 µm and ≥25 µm particles per USP <787> / <788>.
Stability-indicating methods:
• DSF / DSC (differential scanning fluorimetry / calorimetry): Measures thermal unfolding temperatures (Tm, Tonset). Higher Tm correlates with greater conformational stability and lower aggregation propensity.
• Accelerated stability (40°C stress): Incubation at elevated temperature for 2–4 weeks followed by SEC and DLS to predict long-term storage stability from short-term data.
Prevention is far more effective than remediation. Strategies span the entire development cycle:
Sequence-level: Computational tools (spatial aggregation propensity, SAP) identify surface-exposed hydrophobic patches that drive self-association. Point mutations at these sites can dramatically reduce aggregation without affecting binding. Early-stage humanization decisions — particularly framework selection — directly impact aggregation propensity, making developability assessment a critical checkpoint before lead selection.
Process-level: Optimize Protein A elution pH (pH 3.5 is less denaturing than pH 3.0; some antibodies tolerate pH 3.8). Minimize hold times at low pH. Use controlled-rate freezing rather than uncontrolled freezing for bulk drug substance. Avoid vortexing or vigorous mixing of concentrated antibody solutions.
Formulation-level: Buffer choice matters: histidine (pH 5.5–6.5) generally outperforms phosphate for antibody stability. Excipients such as sucrose or trehalose (stabilizers), polysorbate 80 or polysorbate 20 (surfactants to prevent interface-induced aggregation), and arginine (to reduce viscosity at high concentration) are standard components of antibody formulations. The optimal formulation is identified through systematic screening of pH, ionic strength, and excipient combinations using high-throughput DSF and accelerated stability studies.
General industry benchmarks (not regulatory limits):
• Soluble aggregates (SEC): <2% HMW species at release for clinical material. Many programs target <1%.
• Sub-visible particles: ≤6,000 particles ≥10 µm and ≤600 particles ≥25 µm per container (USP <787>).
• Visible particles: Essentially free from visible particulates (Ph. Eur. 2.9.20).
• Stability trend: Aggregate levels should remain within specification through the intended shelf life (typically 18–36 months at 2–8°C). A candidate that starts at 1.5% HMW and reaches 5% within 12 months will not support a viable commercial product.
Dealing with aggregation in your antibody or protein project? AtaGenix offers developability assessment, formulation screening, and process optimization to minimize aggregation from lead selection through manufacturing.
Talk to Technical SupportResponse within 24 hours
Contact Us
+86-27-65523339
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
